Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549915 | 1.00 | OPRL1 (0.49) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL29439759 | 1.00 | OPRL1 (0.49) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL10286357 | 0.89 | P2RX7 (0.45) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL5021376 | 0.89 | P2RX7 (0.45) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL1514902 | 0.89 | P2RX7 (0.45) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL29472109 | 0.89 | P2RX7 (0.45) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL2171553 | 0.87 | P2RX7 (0.44) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL10286331 | 0.87 | P2RX7 (0.44) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL30979862 | 0.87 | P2RX7 (0.44) | OPRL1KCNH2P2RX7HDAC1HDAC6 | |
| SCHEMBL10286334 | 0.87 | P2RX7 (0.44) | OPRL1KCNH2P2RX7HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | claimed |
| EP-3644990-B1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4467199-A2 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2024-11-27 | — | — | EP | disclosed |
| EP-3976597-B1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20230398529-A1 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | US | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0456279-B1 | Condensed piperidine derivatives, intermediates and process for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-01-03 | — | — | EP | disclosed |
| EP-0306356-B1 | CONDENSED PIPERIDINE DERIVATIVES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION , THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-05-19 | — | — | EP | disclosed |
| US-5126353-A | Also used as analgesics, diuretics, hypotensive agents, antiischemic agents | ROUSSEL UCLAF (FR) | 1992-06-30 | — | — | US | disclosed |
| EP-0456279-A1 | Condensed piperidine derivatives, intermediates and process for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1991-11-13 | — | — | EP | disclosed |
| US-4927832-A | DIURETIC, ANTIARRYTHMIA, ANTIISCHEMIC, HYPOTENSIVE | ROUSSEL UCLAF (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0306356-A1 | Condensed piperidine derivatives, intermediates and process for their preparation , their use as medicaments and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398529-A1 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | ADH5, ADH1A, ADH1C | OPRL1 3558/4885KCNH2 551/4885P2RX7 2532/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | OPRL1 1590/4885KCNH2 3269/4885P2RX7 2961/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | OPRL1 3884/4885KCNH2 3080/4885P2RX7 3876/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | OPRL1 2525/4885KCNH2 1859/4885P2RX7 3992/4885 |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, IKBKE | OPRL1 3864/4885KCNH2 3340/4885P2RX7 3760/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | OPRL1 965/4885KCNH2 1074/4885P2RX7 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.